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Background: Poor adherence to antiretroviral therapy (ART) is associated with HIV disease progression and, during
pregnancy, increased mother-to-child transmission risk. In Ukraine, access to combination ART is expanding but data
on adherence are scarce.
Methods: Cross-sectional surveys of HIV-positive women were conducted i) at delivery (on antenatal ART adherence)
and ii) during the first year postpartum (on ART adherence in the preceding four weeks). Factors associated with a
score ≤11 on the self-report Case Adherence Support Evaluation (CASE) index or ≥1 self-reported missed dose were
assessed using Fisher’s exact test.
Results: Of 185 antenatal participants and 102 postnatal participants, median ages were 27.5 and 29.5 years
respectively: 28% (50/180) and 27% (26/98) reported an unplanned pregnancy, and 13% (24/179) and 17% (17/98) an
illicit drug-use history (excluding marijuana). One quarter (49/180 antenatally, 27/101 postnatally) screened positive for
depression. The proportion reporting ‘low’ ART-related self-efficacy (i.e. unable to do ≥1/5 ART-taking activities) was
20% (28/141) antenatally and 17% (11/66) postnatally. Antenatally, 14% (95% CI 10-21%) had a CASE score ≤11 and
35% (95% CI 28-42%) reported missing ≥1 dose. Factors associated with a CASE score ≤11 were unplanned pregnancy
(25% (12/48) vs. 11% (13/120) where planned, p = 0.03) and living with extended family (23% (13/57) vs. 10% (12/125)
living with partner/alone, p = 0.04). Self-report of ≥1 missed dose antenatally was additionally associated with
younger age (p = 0.03) and lower self-efficacy (50% (14/28) reported ≥1 missed dose vs. 28% (30/108) of those
with high self-efficacy, p = 0.04). Of 102 postnatal participants, 8% (95% CI 4-15%) had a CASE score ≤11 and 31%
(95% CI 22-41%) reported ≥1 missed dose. Of 11 women with low self-efficacy, 3 (27%) had a CASE score ≤11
compared with 3/55 (5%) of those with high self-efficacy (p = 0.05). Current smokers more commonly reported ≥1
missed dose postnatally (50% (13/26) vs. 25% (18/72) of non-smokers, p = 0.03).
Conclusions: Our results highlight unmet needs for counselling and support. We identify some groups at risk of
poor ART adherence, including women with markers of social vulnerability and those with low ART-related
self-efficacy, who may benefit from targeted interventions.
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Ukraine is a lower middle-income country which, along
with Russia, accounts for around 90% of new HIV infec-
tions in Eastern Europe [1] – a region with an injecting
drug use (IDU)-driven epidemic which continues to ac-
celerate, in contrast with worldwide trends [2]. Newly
diagnosed HIV infections in Ukraine are now equally
distributed between women and men with adult HIV
prevalence >1% overall [3]. In 2011, AIDS-related morbid-
ity and mortality rates were 8.2 and 20.1 per 100,000 popu-
lation respectively and 44% of AIDS diagnoses were in
individuals not previously aware of their HIV infection [3].
Scale-up of antiretroviral therapy (ART) has been slow,
but access to combination ART (cART) for HIV-positive
pregnant women in Ukraine expanded following the
shift in 2007 from a World Health Organisation (WHO)
Option A policy (i.e. cART for women with treatment
indications and zidovudine monotherapy (ZDVm) for
those who require ART for prevention of MTCT
(PMTCT) only) to an Option B policy (i.e. cART for all
HIV-positive pregnant women) [4]. Antenatal cART
coverage reached 60% in 2010 and 80% in 2011 [3,5].
Access to cART among the general population is also
improving: of ART-eligible individuals in HIV care in
2011, around 70% were receiving cART [3], up from
48% in 2009 [6]. The success of expanded cART cover-
age in improving health outcomes depends on adherence
to treatment, low levels of which are associated with
HIV disease progression, mortality and development of
de novo resistance to antiretroviral drugs [7-9]. During
pregnancy, a compromised virological response to cART
also increases risk of mother-to-child transmission
(MTCT) of HIV [10,11], including of drug resistant virus
[12]. Lower levels of adherence to ART during preg-
nancy have elsewhere been associated with use of illicit
drugs, alcohol and tobacco [13-15], although not con-
sistently [16,17], possibly because of the importance of
context-specific factors, particularly availability of harm
reduction services [18]. Access to opioid substitution
therapy in Ukraine is poor, with only 6,632 of an esti-
mated 250,000 people injecting opiates receiving metha-
done or buprenorphine by the end of 2011 [3].
Information on adherence to ART during pregnancy
and postnatally is essential for the strengthening of
PMTCT and treatment programmes in Ukraine, where
second-line ART options are currently lacking [19]. To
our knowledge, there are no published data on ART ad-
herence in Ukraine and little information available on
adherence more widely in Eastern Europe, particularly
among childbearing women, who may have different
levels of and motivations for adherence than the general
population [20]. In other settings, the immediate post-
partum period has been found to be a time of high risk
for poor ART adherence [13,14,21-23]. The aim of thisstudy was to investigate levels and determinants of self-
reported ART adherence during pregnancy and the first
year postpartum among women with HIV in Ukraine.
Methods
The European Collaborative Study (ECS) is an observa-
tional cohort study of HIV-infected pregnant women
and their infants, active in Ukraine since 2000. At the
time of this study, the ECS was enrolling around 30% of
HIV-positive pregnant women in Ukraine at seven re-
gional HIV/AIDS centres [5]. Linked anonymous data are
collected on maternal and delivery characteristics and in-
fant infection status, following informed consent.
For this investigation of ART adherence during preg-
nancy and postnatally, two cross-sectional surveys were
conducted. The antenatal survey took place at three mater-
nity hospitals among women who had taken ≥4 weeks of
antenatal ART, who were invited to participate during their
postnatal hospital stay (typically of ≥3 days). The postnatal
survey took place at six HIV/AIDS centres among women
attending between 1 and 12 months postpartum for rou-
tine infant follow-up and ongoing HIV care, who were cur-
rently on ART. See the Acknowledgements section for a
full list of participating sites and information on ethics and
institutional approvals. Survey participation was open to all
women meeting the eligibility criteria, regardless of
whether they were enrolled in the ECS. Participants gave
informed consent and completed a paper-based question-
naire. Unique study identifiers allowed clinicians to refer
women for additional support where necessary, while en-
suring participant anonymity to researchers.
The survey period was from July to December 2011,
with extension to April 2012 for sites with operational
problems (e.g. periods of ward closure). We constructed
indirect measures of survey participation for the main
six-month study period. For the antenatal survey, the
number of surveys returned was calculated as a propor-
tion of the 240–300 deliveries to HIV-positive women at
participating hospitals over the main six-month survey
period (of whom 90% were estimated to be eligible [5]).
For the postnatal survey, data from a postnatal cohort
nested within the ECS on number of women attending
HIV care postnatally were used to calculate participation
rates. There were fewer postnatal than antenatal partici-
pants because only around a fifth of women continue
ART after delivery in Ukraine, with many of the remain-
der not yet meeting eligibility criteria for treatment [24].
Survey responses were matched to ECS data using ma-
ternal date of birth, date of delivery, infant sex and
centre, and characteristics of survey participants com-
pared with those of women who did not participate to
explore the survey population’s representativeness. Asso-
ciations between adherence and clinical characteristics
were explored in the subgroup with ECS data available.
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adherence, socio-demographic characteristics, health be-
haviours, disclosure of HIV status, experience of ART
side effects, reasons for missed doses of ART (from the
AIDS Clinical Trials Group adherence tool [25]), symp-
toms of depression and ART-related self-efficacy. Women’s
perceptions of the risks and benefits of ART for PMTCT
were explored using questions from the NIAID Adult AIDS
Clinical Trials Group supplemental antepartum adherence
questionnaire [26]. Postnatally, women were asked if and
how their adherence had changed following delivery (ques-
tion adapted from Mellins et al. [13]).
Definitions
Self-reported adherence to ART was measured using the
Case Adherence Support Evaluation (CASE) index tool.
Answers to three questions (on difficulty taking medica-
tions on time, frequency of missed doses, and timing of
last missed dose) give a score of between 3 and 16, with
higher scores indicating better adherence [27]. Previous
studies validating this tool against viral load have deter-
mined best score cut-offs for defining ‘poor’ ART adher-
ence to be ≤10 [27], ≤11 [28] and ≤12 [29]; in this study, a
score of ≤11 was chosen as it showed the greatest associ-
ation with viral load measures in validation analyses (data
not shown). Responses were also categorised according to
whether any missed doses were reported (one potentially
valid approach [30]); ‘≥1 missed dose’ referred to the
whole of pregnancy in the antenatal survey, and the pre-
ceding four weeks in the postnatal survey.
Symptoms of depression over the last month were
measured using Patient Health Questionnaire-2 Screen-
ing Questions from the Primary Care Evaluation of
Mental Disorders [31], with a positive depression screen-
ing test result defined as self-reported anhedonia and
low mood, or one of these and a positive response to an
enquiry about the need for help [32].
ART-related self-efficacy was measured using five ques-
tions adapted from the HIV Treatment Adherence Self-
Efficacy Scale [33]. Participants indicated their level of
confidence from ‘could not do’ [0 points], ‘fairly confident
I could do’ [1 point] and ‘confident I could do’ [2 points].
Women answering all five questions and scoring <5 were
defined as having low self-efficacy. Two questions about
help-seeking self-efficacy were also included.
Data analysis
Univariable comparisons were assessed with the χ2 test
and the Fisher’s exact test for categorical variables and
the Wilcoxon Mann–Whitney test for medians; unless
otherwise stated, p-values were obtained using two-sided
Fisher’s exact tests. Multivariable analyses were not con-
ducted, because the number of participants and inter-
correlation of many factors associated with poor adherencemeant that statistical power was insufficient to adjust for
confounding. The aim of this work was to characterise
women likely to benefit most from targeted adherence sup-
port, rather than to establish the relative importance of in-
dependent factors. Data were managed using REDCap
electronic data capture tools hosted at University College
London Institute of Child Health [34]. Statistical analyses
were performed using STATA version 11.0 (StataCorp, LP,
College Station, Texas, USA).
Results
A total of 287 women participated in the surveys (185 in
the antenatal and 102 in the postnatal survey); seven
women completed both surveys. Participant characteristics
are shown in Table 1. Of the 185 antenatal study partici-
pants, 106 took part during the main six-month survey
period, giving a participation rate among eligible women
of 39-49% (based on 240–300 HIV-positive women deliv-
ering at participating hospitals in this period, of whom an
estimated 90% - i.e. 216–270 - had taken ≥4 weeks of
antenatal ART and thus met eligibility criteria). Of the
total 102 postnatal participants, 63 took part during the
main six-month survey period at five HIV/AIDS centres
with denominator data available; these 63 women were es-
timated to represent 75% (63/84) of women on ART at
their first visit to the HIV/AIDS centre following delivery.
Postnatal participants completed the survey a median of
5.3 months after delivery, and were a median of two years
older than antenatal participants. Around three-quarters
in each group were living with a husband or partner
(Table 1). In the antenatal survey, 15% (n = 20) of the 132
women living with a husband or partner were also living
with other adult family members, while in the postnatal
survey this proportion was 14% (11/80). Overall, women
living with their family were younger (median age
26.6 years vs. 28.6 years for women living only with a part-
ner or alone in the antenatal survey, Wilcoxon-Mann–
Whitney test p = 0.02) and more likely to have had an un-
planned pregnancy (36% (21/58) vs. 23% (27/120) of those
living only with a partner or alone, χ2 = 3.73 p = 0.05). This
was also the case in the postnatal survey group, although
comparisons were not statistically significant; women liv-
ing with their family had a median age of 27.9 years vs
29.9 years for the rest of the group (Wilcoxon-Mann–
Whitney p = 0.27), and 36% (8/22) had an unplanned
pregnancy vs. 24% (18/75) of those living with a partner
only or alone (χ2 = 1.33 p = 0.25).
ECS data were available for 97 (52%) of antenatal and
44 (43%) of postnatal participants at the time of analysis;
clinical and treatment data on this sub-group are shown
in Table 2, along with ECS data on women who did not
participate in the adherence surveys. In the antenatal
survey, 12% of women were taking mono/dual therapy
(Table 2). Of those on cART and reporting their regimen
Table 1 Characteristics of survey participants
Antenatal survey
(n = 185)
Postnatal survey
(n = 102)
Median age at
participation (IQR)
27.5 years
(25.0, 30.9)
29.5 years
(25.9, 33.5)
Median time since
delivery (IQR)
1 day (1, 2) 5.3 months (2.4, 7.8)
Marital status
Married 100 (54%) 55 (54%)
Cohabiting 51 (28%) 23 (23%)
Single 34 (18%) 24 (24%)
Pregnancy unplanned 50 (28%) 26 (27%)
Living with†
Husband/partner 132 (72%) 80 (79%)
Extended family
(including parents)
60 (33%) 23 (23%)
Living as only
adult in household
12 (7%) 13 (13%)
Disclosure of HIV status†
To husband/partner 135 (74%) 80 (79%)
To family or friend(s) 108 (59%) 55 (54%)
To no one at all 16 (9%) 7 (7%)
Do you have someone
you can rely on to help
you care for your baby?
Yes 164 (91%) 89 (88%)
No 17 (9%) 12 (12%)
Smoking, alcohol
and drug use†
Current smoker 49 (27%) 28 (28%)
Current alcohol use 168 (9%) 8 (8%)
Ever used marijuana 25 (14%) 15 (15%)
Ever used illicit drugs
other than marijuana
24 (13%) 17 (17%)
Severity of ART
side effects
Not bothered by side
effects or only slightly
132 (75%) 76 (76%)
Somewhat or terribly
bothered by side effects
44 (25%) 24 (24%)
Use of support services†
Currently using support group 10 (5%) 21 (21%)
Currently using peer
counselling
10 (5%) 27 (26%)
Currently using social services 40 (22%) 28 (27%)
Currently using adherence
programme
4 (2%) 39 (38%)
†Groups not mutually exclusive.
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59) postnatally were taking a ritonavir-boosted lopinavir-
based regimen. Most women (antenatal: 72% (102/142),postnatal: 56% (40/72)) were taking six antiretroviral pills
a day. Postnatal participants were more likely to have
WHO stage 3–4 disease (39% (16/41) vs. 22% (19/86) of
antenatal participants, χ2 = 3.99 p = 0.05) and had been
taking ART for longer (Table 2, Wilcoxon Mann–Whitney
test p < 0.01), reflecting their indications for treatment ra-
ther than for PMTCT only. Of note, adherence study par-
ticipants had higher levels of education compared with
women enrolled in the ECS only (92% (35/38) remained in
full-time education until ≥17 years of age vs. 74% (595/
799) of women in the ECS only, Fisher’s exact test p =
0.01).
A quarter of women screened positive for depression
(49/180 antenatally and 27/101 postnatally). With regards
ART-related self-efficacy, the area in which women most
commonly lacked confidence was in their ability to keep
taking medication if experiencing side effects (Table 3).
Most reported being able to share concerns with their
clinician, but fewer were able to ask someone for support
with taking their medication (Table 3). Although most
antenatal survey participants were completely (44%, 80/
180) or fairly (51%, 91/180) sure that antenatal ART was
effective for PMTCT, 82% (149/181) were at least a little
worried that it might harm their baby. Women who were
completely sure of the effectiveness of ART were less likely
to be worried about harm (74% (59/80) vs. 88% (80/91) of
those who were only fairly sure of its effectiveness, χ2 =
5.61 p = 0.02).
Prevalence of poor adherence and reasons for
missed doses
Median CASE scores were 15 (of a possible 16) in both
the antenatal survey (n = 173) and the postnatal survey
(n = 99) (antenatal: IQR 13, 16, range 6, 16; postnatal:
IQR 14, 16, range 7, 16). The proportion with a CASE
score ≤11 (defined as ‘poor’ adherence) was 14% (25/
173, 95% CI 10-21%) in the antenatal survey and 8% (8/
99, 95% CI 4-15%) in the postnatal survey, while 35%
(61/176, 95% CI 28-42%) and 31% (31/100, 95% CI 22-
41%) reported having missed ≥1 dose during pregnancy
and in the last four weeks respectively. Antenatally, the
most common reasons for missing a dose were being
away from home (8%, 14/185), forgetting (5%, 10/185)
and feeling sick or ill (5%, 10/185), while postnatally
these were forgetting (15%, 15/102), sleeping through
the dose (9%, 9/102) and being away from home (8%, 8/
102). In the postnatal survey, 13% (12/93) reported hav-
ing missed fewer doses during pregnancy than postna-
tally, 2% (2/93) having missed fewer doses postnatally
than when pregnant, 6% (6/93) having unchanged adher-
ence, and 78% (73/93) having missed no doses in either
time period. Of the 12 women who reported adhering to
ART better during pregnancy than postnatally, 11 cited
concerns about MTCT as a reason for this.
Table 2 Clinical characteristics and ART use among adherence study participants with matched ECS data available, and
their representativeness with respect to women enrolled in the ECS
Adherence study
Antenatal survey and ECS (n=97) Postnatal survey and ECS (n=44) ECS enrolment only (n = 1596)
Age at leaving full-time education
≤16 years 1 (6%) 2 (9%) 204 (26%)
17 years or above 15 (94%) 20 (91%) 595 (74%)
History of injecting drug use
No 87 (90%) 35 (80%) 1398 (88%)
Yes 10 (10%) 9 (20%) 191 (12%)
History of pregnancy termination
0 40 (45%) 14 (39%) 540 (41%)
1 27 (31%) 8 (22%) 338 (26%)
2 or more 21 (24%) 14 (39%) 435 (33%)
Timing of HIV diagnosis
Before pregnancy 44 (46%) 23 (52%) 693 (44%)
1st/2nd trimesters 48 (50%) 21 (48%) 736 (46%)
3rd trimester/intrapartum 4 (4%) 0 159 (10%)
Antenatal CD4 count
(first in pregnancy)
≤350 cells/mm3 19 (28%) 26 (76%) 484 (39%)
>350 cells/mm3 48 (72%) 8 (24%) 773 (61%)
WHO stage
1-2 67 (78%) 25 (61%) 1160 (81%)
3-4 19 (22%) 16 (39%) 269 (19%)
Timing of ART initiation
Before conception 7 (8%) 7 (17%) 95 (7%)
1st/2nd trimester 61 (66%) 23 (56%) 929 (65%)
3rd trimester 25 (27%) 11 (27%) 402 (28%)
Antenatal ART regimen
Mono/dual 11 (12%) 3 (7%) 314 (22%)
cART 83 (88%) 39 (93%) 1139 (78%)
Median weeks on ART by
completion of adherence survey
13.7 (IQR 11.3, 17) 43.7 (IQR 26.0, 54.9)
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during pregnancy
Table 4 shows factors associated with a CASE score ≤11
and with reporting ≥1 missed dose during pregnancy.
Women living with their extended family (a factor corre-
lated with youth and unplanned pregnancy) were more
likely to report poor adherence, particularly if they had
not disclosed their HIV status to a family member (40%
(8/20) of whom had a CASE score ≤11 vs. 14% (5/37)
living with family who had disclosed their status to a
family member, p = 0.04). Overall however, disclosure of
HIV status to at least one other person (reported by 91%
(167/183) of women) was not associated with adherence
(Table 4). Among married/cohabiting women, 83%(124/150) had disclosed their HIV status to their part-
ner, of whom 32% (37/116) reported missing ≥1 dose
during pregnancy compared with 42% (11/26) who had
not disclosed their HIV status to their partner (p = 0.36).
There was some evidence of an association between
current smoking and reporting of ≥1 missed dose during
pregnancy (p = 0.07), but not between history of illicit drug
use and adherence (Table 4). A positive depression screen-
ing test result was weakly associated with increased likeli-
hood of reporting ≥1 missed dose (Table 4). Adherence
did not differ by whether ART was perceived as safe (p =
1.00 for ≥1 missed dose), but there was some evidence
that adherence was poorer among the small group of
women unsure of the effectiveness of ART for PMTCT
Table 3 Measures of self-efficacy
Antenatal survey Postnatal survey
Confident
could do
Fairly confident
could do
Could
not do
Confident
could do
Fairly confident
could do
Could
not do
ART-related self-efficacy
1. Keep taking ART if side effects interfere 40% (68/171) 46% (78/171) 15% (25/171) 29% (26/89) 51% (45/89) 20% (18/89)
2. Keep taking ART in front of people
unaware of your HIV status
43% (75/175) 46% (81/175) 11% (19/175) 31% (27/88) 59% (52/88) 10% (9/88)
3. Keep taking ART if daily routine disrupted 45% (78/173) 47% (81/173) 8% (14/173) 41% (35/86) 57% (49/86) 2% (2/86)
4. Keep taking ART if not feeling well 43% (77/178) 47% (83/178) 10% (18/178) 24% (20/85) 62% (53/85) 14% (12/85)
5. Keep attending appointments if
they interfere with daily activities
36% (54/148) 55% (82/148) 8% (12/148) 45% (32/71) 52% (37/71) 3% (2/71)
Proportion reporting that they could
not do ≥1 of 5 ART-related items
20% (28/141) 17% (11/66)
Help-seeking self-efficacy
1. Ask clinician for more information
or tell them about concerns or worries
37% (61/167) 56% (94/167) 7% (12/167) 48% (41/86) 49% (42/86) 3% (3/86)
2. Ask someone for support with
taking medication if needed
33% (54/165) 47% (78/165) 20% (33/165) 30% (26/86) 43% (37/86) 27% (23/86)
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to report ≥1 missed dose compared with those on cART
(Table 4, p = 0.02), while those who were confident to ask
their doctor for support had higher CASE scores than
those who reported that they could not do this (Table 4).
However, there was no difference in adherence by severity
of HIV disease (13% (8/64) and 11% (2/17) of women with
WHO stage 1–2 and 3–4 disease had a CASE score
of ≤11 respectively, p = 1.00; subgroup with ECS data).
Factors associated with poor adherence in the year
following delivery
Factors associated with a CASE score ≤11 or with report-
ing ≥1 missed dose in the last four weeks in the postnatal
survey are shown in Table 5. Current smokers were more
likely to report ≥1 missed dose, as were women with a his-
tory of illicit drug use and those not using a treatment ad-
herence programme (p = 0.08 for latter two factors,
Table 5). Women who had not disclosed their HIV status
to anyone were more likely to report having missed ≥1
dose, and there was some indication of lower ART adher-
ence among unmarried and single women (vs. married
women) and those not living with a partner (Table 5), al-
though small numbers limited statistical power. Women
with low self-efficacy were more likely to have a CASE
score ≤11, but there was no association between adher-
ence and depression screening test result postnatally and
severity of self-reported ART side effects was also not as-
sociated with adherence (Table 5). Of the subgroup with
ECS data available, 36% (9/25) of women with WHO stage
1–2 disease reported having missed a dose in the last four
weeks vs. 13% (2/16) of those with WHO stage 3–4
disease (p = 0.15).Discussion
In this cross-sectional study of ART adherence in child-
bearing women in Ukraine, poor adherence (defined as a
score of ≤11 on the CASE adherence index measure)
was reported by 14% (95% CI 10-21%) of women during
pregnancy and 8% (95% CI 4-15%) of women in their
first year postpartum. A third of women in the antenatal
survey reported missing at least one dose during preg-
nancy, and a similar proportion postnatally reported
missing at least one dose in the preceding four weeks.
Cross-study comparisons of ART adherence are prob-
lematic due to the range of assessment methods and
outcomes used; a recent meta-analysis estimated that
72% of women took >80% of ART doses during preg-
nancy [20], but self-reported measures (as used in this
study) are generally inflated compared with more object-
ive measures [35-37]. Despite fairly high levels of adher-
ence in our study, most women (>80%) were worried
about the safety of antenatal ART, a quarter screened
positive for depression, and one in four reported being
somewhat or terribly bothered by ART side effects. Un-
met need for support may impact on the sustainability
of ART adherence beyond pregnancy and the first year
following delivery.
Levels of adherence reported during and after pregnancy
were similar, but there were important differences between
the survey groups, particularly with respect to HIV disease
stage, reflecting the fact that a large proportion of HIV-
positive women stop ART after delivery in this setting, as
they lack indications for treatment. Risk of disengagement
from HIV care is high in the postnatal period, and women
with risk factors for poor adherence may have been
under-represented in our postnatal survey if they were
Table 4 Factors associated with poor ART adherence during pregnancy
CASE score ≤11
points (25/173)
Fisher’s exact test ≥1 missed
dose (61/176)
Fisher’s exact test
Age
<25 years 26% (11/42) p = 0.13 52% (23/44) p = 0.03
25-27 years 10% (5/48) 23% (11/48)
28-30 years 12% (5/41) 29% (12/41)
≥31 years 10% (4/42) 35% (15/43)
Marital status
Married 14% (13/93) p = 0.96 34% (32/95) p = 0.83
Cohabiting 15% (7/48) 33% (16/48)
Single 16% (5/32) 39% (13/33)
Pregnancy planned
Yes 11% (13/120) p = 0.03 30% (36/122) p = 0.02
No 25% (12/48) 49% (24/49)
Lives with family
No 10% (12/115) p = 0.04 29% (34/117) p = 0.04
Yes 23% (13/57) 46% (26/57)
Lives with partner
No 18% (9/49) p = 0.47 45% (22/49) p = 0.08
Yes 13% (16/123) 30% (38/125)
Disclosed HIV status to anyone
No 20% (3/15) p = 0.46 38% (6/16) p = 0.79
Yes 14% (22/157) 35% (55/159)
Current smoker
No 14% (18/127) p = 1.00 30% (39/129) p = 0.07
Yes 14% (6/44) 47% (21/45)
History of drug use (other than marijuana)
No 14% (21/146) p = 1.00 35% (52/149) p = 1.00
Yes 14% (3/21) 33% (7/21)
Self-efficacy score
≥5 (higher self-efficacy) 12% (13/107) p = 0.22 28% (30/108) p = 0.04
<5 (lower self-efficacy) 22% (6/27) 50% (14/28)
Positive depression screen
No 13% (16/124) p = 0.33 31% (39/125) p = 0.08
Yes 20% (9/46) 46% (22/48)
Can you ask doctor for support?
Certain/fairly certain 14% (21/155) p = 0.06 33% (52/156) p = 0.34
Cannot do 36% (4/11) 50% (6/12)
Antenatal ART
Zidovudine monotherapy 29% (4/14) p = 0.23 64% (9/14) p = 0.02
cART 13% (19/141) 31% (44/143)
Severity of ART side effects
Not bothered or only slightly 14% (18/126) p = 0.81 33% (42/127) p = 0.71
Somewhat or terribly bothered 16% (7/43) 37% (16/43)
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Table 4 Factors associated with poor ART adherence during pregnancy (Continued)
Knowledge of whether antenatal ART is effective for PMTCT
Completely or fairly sure that it is effective 12% (20/162) p = 0.10 33% (54/165) p = 0.17
Unsure that it is effective 33% (3/9) 56% (5/9)
p values ≤0.5 are indicated in bold.
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http://www.biomedcentral.com/1471-2458/14/993also more likely to disengage from care after delivery. We
therefore could not make meaningful comparisons of ad-
herence between the two time periods. Women receiving
antenatal ZDVm reported poorer adherence overall than
those receiving cART, possibly because ZDVm is used
preferentially among women with indicators of social dis-
advantage [5], and because women initiating cART may
receive more intensive adherence counselling. ZDVm
(WHO Option A) is no longer recommended by the
WHO for PMTCT [38]; the shift in international guide-
lines towards lifelong cART for all pregnant HIV-positive
women (WHO Option B+) [38] underscores the import-
ance of adherence support continuing postpartum for the
success of future treatment programmes [39]. Of note, a
minority (12/93) of postnatal respondents reported a de-
cline in adherence following delivery but only two re-
ported an improvement. We were therefore not able to
rule out poorer levels of adherence postpartum, as has
been reported elsewhere [13,14,21-23].
Poor adherence during pregnancy was more commonly
reported among women living with their extended family,
women not living with a partner, younger women and
those with an unplanned pregnancy (factors which were
inter-related). Lack of financial support from a partner has
been associated with poor ART adherence among women
in South Africa [40], and younger age with increased risk
of poor ART adherence and/or poor virological outcomes
in the UK and North America [41-43], including among
pregnant and postpartum women [16,17]. Our findings on
the association between poor adherence and lack of dis-
closure to family members among the sub-group of
women living with their extended family highlight the im-
portance of providing support for disclosure within the
household. Of note, 1 in 10 women reported being unable
to take ART in front of someone who was unaware of
their HIV status.
Women with other specific poor health behaviours
were more likely to report poor adherence. This in-
cluded current smokers, who were more likely to re-
port having missed a dose (statistically significant only
postnatally), and are a generally less affluent group
[44]. There was some evidence of an association be-
tween history of drug use and poor ART adherence
postnatally but not during pregnancy in our study. IDUs
engaged with PMTCT interventions (and particularly
those having taken antenatal ART for ≥4 weeks – an inclu-
sion criteria for this study) may be a select group betterable to adhere than those receiving ART for their own
health postnatally.
Lower ART-related self-efficacy was associated with
self-report of ≥1 missed dose during pregnancy and a
CASE score ≤11 postnatally. Women with a positive de-
pression screening test were also slightly less likely to re-
port complete antenatal adherence (p = 0.08). Cognitive-
behavioural interventions to increase self-efficacy have
been associated with reduced depressive symptoms, in-
creases in CD4 count and decreases in viral load among
HIV-positive women in the US [45,46], and are a potential
area for intervention in this population. CASE scores ≤11
were more common antenatally among women not
confident to seek information and support from their doc-
tor. The time needed to build a positive, trusting relation-
ship with a healthcare provider, of potential importance to
adherence behaviours [47,48], is limited before initiating
ART during pregnancy. Pregnant women have specific
counselling needs regarding ART preparedness – e.g. the
exacerbation of side effects by physical changes during
pregnancy [14] – and our results highlight areas for im-
provement, particularly around the risks and benefits of
ART. As the number of HIV-positive pregnant women in
Ukraine increases and ART coverage expands [3,5], strat-
egies are needed to ensure sustainable delivery of high-
quality counselling. Support services were most commonly
used in our sample after delivery, suggesting that access
could be improved in pregnancy. Women using treatment
adherence programmes were more likely to report good
adherence postnatally, but further work is needed to assess
the impact of these programmes in specific groups.
This study is limited by its use of a self-report adher-
ence measure which, while shown to be associated with
virological response [27-29], is likely to over-estimate
actual levels of adherence. The sample size of the sur-
veys and the lack of variability in CASE scores limited
statistical power to detect differences in ART adher-
ence by maternal characteristics, particularly postpar-
tum, as the proportion of women eligible to continue
ART after delivery and their long follow-up intervals
and loss to follow-up [24] restricted the number of
women eligible and available to participate. The trends
in characteristics of participants who reported ≥1
missed dose (the more sensitive of the two outcome
measures studied) were broadly similar to those with a
CASE score ≤11 points in the antenatal survey, with the
exception of smokers and those not living with a
Table 5 Factors associated with poor ART adherence in the year following delivery
CASE score ≤11
points (8/99)
Fisher’s exact test ≥1 missed
dose (31/100)
Fisher’s exact test
Age
<25 years 9% (2/22) p = 0.95 23% (5/22) p = 0.37
25-27 years 7% (1/15) 19% (3/16)
28-30 years 5% (1/21) 29% (6/21)
≥31 years 10% (4/40) 40% (16/40)
Marital status
Married 6% (3/54) p = 0.13 22% (12/55) p = 0.08
Cohabiting 19% (4/21) 38% (8/21)
Single 4% (1/24) 46% (11/24)
Lives with family
No 8% (6/75) p = 1.00 30% (23/76) p = 0.80
Yes 9% (2/23) 35% (8/23)
Lives with partner
No 10% (2/21) p = 0.68 48% (10/21) p = 0.11
Yes 8% (6/77) 27% (21/78)
Disclosed HIV status to anyone
No 14% (1/7) p = 0.46 71% (5/7) p = 0.03
Yes 8% (7/91) 28% (26/92)
Current smoker
No 6% (4/71) p = 0.20 25% (18/72) p = 0.03
Yes 15% (4/26) 50% (13/26)
History of drug use (other than marijuana)
No 8% (6/78) p = 0.63 28% (22/79) p = 0.08
Yes 12% (2/17) 53% (9/17)
Using treatment adherence programme
No 7% (4/60) p = 0.71 38% (23/61) p = 0.08
Yes 10% (4/39) 21% (8/39)
Self-efficacy score
≥5 (higher self-efficacy) 5% (3/55) p = 0.05 36% (20/55) p = 0.32
<5 (lower self-efficacy) 27% (3/11) 55% (6/11)
Positive depression screen
No 7% (5/71) p = 0.68 28% (20/72) p = 0.46
Yes 11% (3/27) 37% (10/27)
Severity of ART side effects
Not bothered or only slightly 8% (6/74) p = 1.00 29% (22/75) p = 0.46
Somewhat or terribly bothered 8% (2/24) 38% (9/24)
p values ≤0.5 are indicated in bold.
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http://www.biomedcentral.com/1471-2458/14/993partner, for whom an increased risk of ≥1 missed dose
was detected but not an increased risk of having a
CASE score ≤11 points. In the postnatal survey,
women not living with a partner were also at increased
risk of ≥1 missed dose but not a CASE score ≤11
points, as were women who had not disclosed their
HIV status to anyone, single women, those with ahistory of drug use, and those not using a treatment
adherence programme. This partly reflects greater stat-
istical power to detect differences by reporting of ≥1
missed dose compared with CASE score ≤11 (due to
the larger number of women reaching the more sensi-
tive cut-off ), but possibly also the characteristics of
women with early indications of adherence problems.
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women in the antenatal survey and around 75% of eligible
women on ART in the postnatal survey. Importantly, some
women most at risk of poor adherence may have been ex-
cluded due to our eligibility criteria (of note, survey partici-
pants were more highly educated than women enrolling
only in the ECS) and we may therefore have over-estimated
adherence levels in the populations of interest.
Our study design and the use of both WHO Option A
and Option B strategies for women requiring ART for
PMTCT precluded comparison of adherence during
pregnancy and after delivery; future longitudinal studies
are needed to assess changes in adherence over time in
the subgroup of women who have treatment indications
for their own health and continue ART postnatally.
Conclusions
Our results highlight unmet needs for counselling and
support and identify some risk groups – particularly
women with markers of social vulnerability, substance
users and those with low ART-related self-efficacy –
who may benefit from targeted interventions to support
ART adherence during pregnancy and postnatally.
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